A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

Publications

Download the full research reports and methodologies from the Foundation's three research programmes, as well as studies, articles and briefing papers on how pharmaceutical companies address specific access-to-medicine priorities.

All Access to Medicine Index Access to Vaccines Index AMR Benchmark Thematic studies Articles Viewpoints

published on 19 Nov 2008

2008 Access to Medicine Index Industry and Stakeholder Review

Report describing the methodology for the 2008 Access to Medicine Index and how it was developed. It includes a set of ambitious, yet achievable expec...

Learn more

published on 02 Jun 2008

2008 Access to Medicine Index

2008 ranking of the top 20 pharmaceutical companies based on their access-to-medicine performances for high-burden diseases in low- and middle-income...

Learn more

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |